<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02642289</url>
  </required_header>
  <id_info>
    <org_study_id>UAL-270415</org_study_id>
    <nct_id>NCT02642289</nct_id>
  </id_info>
  <brief_title>Probiotics: Clinical Intervention Trial in Patients With Fibromyalgia</brief_title>
  <official_title>Probiotics: Clinical Intervention Trial in Patients With Fibromyalgia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pablo Román López</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidad de Almeria</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the benefits of probiotics in patients with fibromyalgia syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Probiotics has demonstrated to be effective in the management of anxiety and depression.
      Although these results are promising, more research is needed to explore the role of
      probiotics to improve physical, emotional and cognitive processes in different clinical
      populations that are associated with altered microbiome. Thus, the main aim of the present
      project is to explore whether the oral intake of probiotics might provide benefits to a group
      of patients with fibromyalgia.

      The investigators expect to found significant differences between some physical, emotional
      and cognitive measures assessed pre- and post-treatment demonstrating the effects of
      microbiota on the Central Nervous System as well as its potential as a therapeutic tool for
      the treatment of Fibromyalgia.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change Scores on Working memory and attentional control</measure>
    <time_frame>Time Frame: At baseline and 8 weeks</time_frame>
    <description>Corsi task</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change Scores on Body Composition</measure>
    <time_frame>Time Frame: At baseline and 8 weeks</time_frame>
    <description>Fat mass. Body fat mass. Intracellular water. Extracellular water. Fat-free mass. Total body water.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes Scores on Cholinergic response indicators (%)</measure>
    <time_frame>Time Frame: At baseline and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes Scores on Heart rate variability.</measure>
    <time_frame>Time Frame: At baseline and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes Scores on Valsalva ratio. K30/15.</measure>
    <time_frame>Time Frame: At baseline and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes Scores on Systemic vascular resistance.</measure>
    <time_frame>Time Frame: At baseline and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change Scores on Pain</measure>
    <time_frame>Time Frame: At baseline and 8 weeks</time_frame>
    <description>Index of Widespread Pain and Symptom Severity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change Scores on Sleep Quality</measure>
    <time_frame>Time Frame: At baseline and 8 weeks</time_frame>
    <description>Pittsburgh Sleep Quality Index Questionnaire (PSQI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change Scores on Quality of Life</measure>
    <time_frame>Time Frame: At baseline and 8 weeks</time_frame>
    <description>The assessment of Quality of Life (SF-36)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change Scores on Depression</measure>
    <time_frame>Time Frame: At baseline and 8 weeks</time_frame>
    <description>The Beck inventory for depression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change Scores on Stress</measure>
    <time_frame>Time Frame: At baseline and 8 weeks</time_frame>
    <description>Determination of cortisol in urine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change Scores on Anxiety</measure>
    <time_frame>Time Frame: At baseline and 8 weeks</time_frame>
    <description>The State-Trait Anxiety Inventory (STAI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change Scores on Impulsivity</measure>
    <time_frame>Time Frame: At baseline and 8 weeks</time_frame>
    <description>The Two-choice task</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Fibromyalgia</condition>
  <arm_group>
    <arm_group_label>Probiotic1: Lactobacillus acidophilus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dietary Supplement: Probiotics 1. 8-week probiotic food-supplement intervention with Lactobacillus acidophilus (Daily intake: 24 millions)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Inactivate substance</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Probiotic2: Lactobacillus Rhamnosus GG ®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dietary Supplement: Probiotics 2 8-week probiotic food-supplement intervention with Lactobacillus Rhamnosus (Daily intake: 24 millions)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lactobacillus acidophilus</intervention_name>
    <description>Probiotic 5000, a commercial probiotic product provided by the company &quot;Complementos Fitonutricionales, S.L.&quot;</description>
    <arm_group_label>Probiotic1: Lactobacillus acidophilus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lactobacillus Rhamnosus GG ®</intervention_name>
    <description>Ergyphilus confort, a commercial probiotic product provided by the nutritional supplements lab &quot;Laboratorios Nutergia&quot;</description>
    <arm_group_label>Probiotic2: Lactobacillus Rhamnosus GG ®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Innocuous substance</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Fibromyalgia syndrome diagnosis.

          -  No treatment with antibiotic.

          -  More than a year of diagnosis

          -  Agreement to participate in the study.

        Exclusion Criteria:

          -  Severe physical disability.

          -  Malignancy.

          -  Pregnancy

          -  Psychiatric illnesses (eg, schizophrenia or substance abuse).

          -  Medication usage other than as-needed analgesics (excluding long-term narcotics).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Angeles Fernandez, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidad de Almeria</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pablo Roman</name>
      <address>
        <city>Almeria</city>
        <zip>04120</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2015</study_first_submitted>
  <study_first_submitted_qc>December 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 30, 2015</study_first_posted>
  <last_update_submitted>March 11, 2016</last_update_submitted>
  <last_update_submitted_qc>March 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Universidad de Almeria</investigator_affiliation>
    <investigator_full_name>Pablo Román López</investigator_full_name>
    <investigator_title>PhD Student</investigator_title>
  </responsible_party>
  <keyword>Probiotics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibromyalgia</mesh_term>
    <mesh_term>Myofascial Pain Syndromes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

